ImmunityBio Announces Study Of ANKTIVA In Combination With The AdHER2DC Cancer Vaccine As A Potential Therapy To Control Endometrial Cancer
Portfolio Pulse from Benzinga Newsdesk
ImmunityBio, Inc. (IBRX) has announced the initiation of the QUILT 502 trial to study the combination of ANKTIVA and the AdHER2DC vaccine for treating HER2-positive endometrial cancer. The trial will also include pembrolizumab and lenvatinib, and aims to evaluate the safety and preliminary efficacy of this combination therapy. The study is expected to be completed in 2026.
August 06, 2024 | 1:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ImmunityBio, Inc. (IBRX) has initiated the QUILT 502 trial to study the combination of ANKTIVA and the AdHER2DC vaccine for HER2-positive endometrial cancer. The trial will also include pembrolizumab and lenvatinib, and aims to evaluate the safety and preliminary efficacy of this combination therapy. The study is expected to be completed in 2026.
The initiation of the QUILT 502 trial represents a significant step for ImmunityBio in expanding the use of ANKTIVA in combination with other therapies for treating HER2-positive endometrial cancer. The inclusion of FDA-approved drugs pembrolizumab and lenvatinib adds credibility to the trial. The long-term potential of this combination therapy could positively impact IBRX's stock price in the short term as investors react to the news.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100